{
    "organizations": [],
    "uuid": "277bfd794eed6a06875c30c05453244118ea384f",
    "author": "",
    "url": "https://www.reuters.com/article/brief-neptune-and-tetra-bio-pharma-sign/brief-neptune-and-tetra-bio-pharma-sign-co-development-agreement-idUSFWN1Q211O",
    "ord_in_thread": 0,
    "title": "BRIEF-Neptune And Tetra Bio-Pharma Sign Co-Development Agreement",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 08 PM / in 11 minutes BRIEF-Neptune And Tetra Bio-Pharma Sign Co-Development Agreement Reuters Staff 1 Min Read \nFeb 12 (Reuters) - Tetra Bio Pharma Inc: \n* NEPTUNE AND TETRA BIO-PHARMA ENTER CO-DEVELOPMENT AGREEMENT FOR PURIFIED CANNABINOID OIL-BASED PRODUCTS TARGETING PAIN AND INFLAMMATION \n* TETRA BIO PHARMA- CO,NEPTUNE TECHNOLOGIES & BIORESSOURCES ENTERED DEAL FOR CO-DEVELOPMENT, COMMERCIALIZATION OF PURIFIED CANNABINOID OIL-BASED PRODUCTS Source text for Eikon:  ",
    "published": "2018-02-12T15:07:00.000+02:00",
    "crawled": "2018-02-12T15:26:49.026+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "minute",
        "tetra",
        "sign",
        "agreement",
        "reuters",
        "staff",
        "min",
        "read",
        "feb",
        "reuters",
        "tetra",
        "bio",
        "pharma",
        "inc",
        "neptune",
        "tetra",
        "enter",
        "agreement",
        "purified",
        "cannabinoid",
        "product",
        "targeting",
        "pain",
        "inflammation",
        "tetra",
        "bio",
        "co",
        "neptune",
        "technology",
        "bioressources",
        "entered",
        "deal",
        "commercialization",
        "purified",
        "cannabinoid",
        "product",
        "source",
        "text",
        "eikon"
    ]
}